作者: Naruto Shimonishi , Keiji Nogami , Kenichi Ogiwara , Tomoko Matsumoto , Fumie Nakazawa
DOI: 10.1111/HAE.13961
关键词:
摘要: Introduction Emicizumab is an antifactor (F)IXa/FX bispecific antibody, mimicking FVIIIa cofactor function. Emi prophylaxis effectively reduces bleeding events in patients with haemophilia A. The physical properties of emicizumab-induced fibrin clots remain to be investigated, however. Aim We have investigated the stability and structure clots. Methods Coagulation was initiated by activated partial thromboplastin time (aPTT) trigger prothrombin (PT)/aPTT-mixed FVIII-deficient plasma various concentrations emicizumab or recombinant FVIII. turbidity were assessed clot waveform clot-fibrinolysis analyses, respectively. resulting analysed scanning electron microscopy (SEM). Results Using aPTT trigger, decreased fibrinolysis times prolonged presence dose-dependently. Scanning imaging demonstrated that improved network thinner fibres than its absence. Although shortened dramatically, nature did not reflect hypercoagulable state. Similarly, using a PT/aPTT-mixed could evaluate potential activity, series experiments. In this circumstance, at 50 100 µg/mL appeared comparable those FVIII ~12 ~24-32 IU/dL, Conclusion plasma, similar